Squarepoint’s Milestone Pharmaceuticals MIST Stock Holding History

Squarepoint’s Portfolio MIST Stock Details MIST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$401K	Buy	336,825 +87,481	+35%	+$153K	﹤0.01%	3485
2025 Q4	$504K	Buy	+249,344	New	+$537K	﹤0.01%	3214
2025 Q1	–	Sell	-56,751	Closed	-$134K	–	5098
2024 Q4	$134K	Buy	56,751 +2,506	+5%	+$4.3K	﹤0.01%	4616
2024 Q3	$82.5K	Sell	54,245 -439	-0.8%	-$639	﹤0.01%	3910
2024 Q2	$72.7K	Buy	+54,684	New	+$87.9K	﹤0.01%	3856
2023 Q4	–	Sell	-41,109	Closed	-$127K	–	4296
2023 Q3	$127K	Sell	41,109 -4,585	-10%	-$14.3K	﹤0.01%	3525
2023 Q2	$130K	Buy	+45,694	New	+$172K	﹤0.01%	3314
2021 Q1	–	Sell	-23,633	Closed	-$158K	–	3424
2020 Q4	$158K	Buy	+23,633	New	+$158K	﹤0.01%	2603

Other funds holding MIST

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Squarepoint's MIST Position: Q1 2026 in Review

Squarepoint increased its Milestone Pharmaceuticals (MIST) stake by 35% in Q1 2026, buying an estimated $153K and bringing the position to 336,825 shares worth $401K. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

Squarepoint first reported a position in MIST in Q4 2020 and has held it in 8 quarters since. The position peaked at $504K in Q4 2025. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

Squarepoint held 336,825 shares of Milestone Pharmaceuticals worth $401K as of Q1 2026.
Squarepoint bought 87,481 Milestone Pharmaceuticals shares in Q1 2026, an estimated $153K.
Milestone Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3485 holding.
Squarepoint first reported a position in Milestone Pharmaceuticals in Q4 2020 and has held it in 8 quarters since.
Squarepoint's Milestone Pharmaceuticals position peaked at $504K in Q4 2025.
86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.